Kyongbo Pharmaceutical Co Ltd Cash Flow Quality Index
Kyongbo Pharmaceutical Co Ltd cash flow quality index. Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow Quality Index of -0.19x as of June 2026. Operating cash flow of ₩-565.17 Million is below net income of ₩2.97 Billion, suggesting accrual-heavy earnings not yet converted to cash. See 214390 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Kyongbo Pharmaceutical Co Ltd (2014–2025)
Cash flow quality index of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. Historical Cash Flow Quality Index for Kyongbo Pharmaceutical Co Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 214390 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Kyongbo Pharmaceutical Co Ltd Cash Flow Quality Index by Year (2014–2025)
Kyongbo Pharmaceutical Co Ltd cash flow quality index by year from 2014 to 2025. Year-by-year earnings quality comparison for Kyongbo Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 214390 cash flow metrics.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 40.90x | ₩7.46 Billion | ₩182.29 Million | ▲ +127144.6% |
| 2024 | 0.03x | ₩149.12 Million | ₩4.64 Billion | ▼ -98.0% |
| 2023 | 1.63x | ₩4.84 Billion | ₩2.97 Billion | ▼ -90.2% |
| 2022 | 16.59x | ₩10.13 Billion | ₩610.59 Million | ▲ +650.0% |
| 2020 | 2.21x | ₩20.80 Billion | ₩9.40 Billion | ▼ -50.6% |
| 2019 | 4.48x | ₩23.67 Billion | ₩5.29 Billion | ▲ +5260.6% |
| 2018 | -0.09x | ₩-1.14 Billion | ₩13.12 Billion | ▼ -106.0% |
| 2017 | 1.44x | ₩25.81 Billion | ₩17.96 Billion | ▼ -27.9% |
| 2016 | 1.99x | ₩25.33 Billion | ₩12.71 Billion | ▲ +1127.5% |
| 2015 | 0.16x | ₩4.24 Billion | ₩26.11 Billion | ▼ -91.3% |
| 2014 | 1.86x | ₩16.04 Billion | ₩8.64 Billion | — |